I. MODIFIED AGREEMENTS |
|||
Biotech Co.* (Country; Symbol) | Biotech Co.* (Country; Symbol) | Change from | Terms/Details (Date) |
|
| |||
Chiron Corp. | Procyon Biopharma | Extended license option agreement for the evaluation of Procyon's prostate secretory protein technology in the treatment of late-stage prostate cancer | The extension gave Chiron exclusivity until Sept. 30 to evaluate the PSP94 technology; Chiron may exercise its right to negotiate a worldwide license to the PSP94 technology (7/12) |
| |||
Dyax Corp. | Genzyme Corp. | Modified collaboration that increases the line of credit from Genzyme to Dyax from $3M to $7M | The collaboration is to develop the kallikrein inhibitor DX-88; the restructured agreement also provides Dyax with an option to acquire Genzyme's interest in the potential application of DX-88 for the prevention of blood loss and other sys- temic inflammatory responses in cardiopulmonary bypass and other surgeries (6/4) |
| |||
Genentech | VaxGen Inc. | Revised May 1997 license and supply agreement to give VaxGen greater flexibility in commercializing its AIDS vaccine candidate, AIDSVax | Genentech maintained its option to market and sell the vaccine in North America, but relinquished its option to the rest of the world; it also reduced VaxGen's royalty obligations for sales to the World Health Organization or United Nations for under- developed countries by up to 50% (7/3) |
| |||
Inhale Therapeutic Systems Inc. (INHL) | Chiron Corp. | Modified agreement to develop an additional inhaleable antibiotic | The companies entered a collaboration in December 2001 to develop a next-generation inhaled powder tobramycin product and to explore developing inhaled antibiotics; based on research, the companies will develop an inhaleable powdered version of PA2794 (7/17) |
| |||
Signature BioScience | geneticXchange Inc.* | Expanded relationship to increase the use of the geneticXchange discovery- Hub product | The product facilitates Signature's data integration on proteins and pathways gathered from its microwave-based spectroscopy in order to understand the relationships between targets (6/4) |
| |||
The Immune Response Corp. | Trinity Medical Group USA Inc. (OTC BB: | Amended Remune license and collaboration contract calling for an additional $50 per unit to be paid to IR for the first 1M doses of Remune purchased by Trinity | Trinity will receive shares of Immune Response common stock and a waiver of the final, optional $5M milestone payment for the technology transfer of Remune manufacturing rights in Trinity's licensed territories; Trinity would receive 2M shares upon the Thai government's approval of the HIV drug in exchange for the $5M milestone payment to Immune Response (6/28) |
| |||
Vical Inc. | Centocor Inc. | Expanded option and license agreement to use Vical's naked DNA technology to develop DNA vaccines for cancer | The expansion of the 1998 agreement will provide an undisclosed up-front payment to Vical, and it could lead to milestone payments and royalties; the specifics of the expansion were not disclosed (6/18) |
II. TERMINATED AGREEMENTS |
|||
Biotech Co.* (Country; Symbol) | Biotech Co.* (Country; Symbol) | Change from | Terms/Details (Date) |
|
| |||
British Biotech | BresaGen | Terminated agreement to develop the GM-CSF antagonist E21R | The decision was made following the re- lease of preclinical data that failed to confirm earlier data on E21R-induced apoptosis in acute myeloid leukemia cells (7/23) |
|
| |||
Notes: | |||
# The information in the chart does not cover agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
LSE = London Stock Echange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulleting Board; TSE = Toronto Stock Exchange | |||
To read more on related topics, click on one of the words below.